Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Johnson and Johnson
Baxter
Harvard Business School
McKinsey

Last Updated: January 29, 2022

DrugPatentWatch Database Preview

Claims for Patent: 7,998,734

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 7,998,734
Title:Methods and compositions for use in gene therapy for treatment of hemophilia
Abstract: The invention includes a composition comprising a recombinant adeno-associated viral vector comprising at least two adeno-associated virus inverted terminal repeats, a promoter/regulatory sequence, isolated DNA encoding Factor IX and accompanying 5\' and 3\' untranslated regions and a transcription termination.
Inventor(s): High; Katherine A. (Merion, PA), Herzog; Roland W. (Glenolden, PA)
Assignee: The Children\'s Hospital of Philadelphia (Philadelphia, PA)
Application Number:11/932,017
Patent Claims:1. A pharmaceutical composition comprising a virus, said virus comprising a recombinant adeno-associated virus vector comprising at least two adeno-associated virus inverted terminal repeats, a promoter/regulatory sequence, isolated DNA encoding Factor IX and accompanying 5' and 3' untranslated regions and a transcription termination sequence, wherein said isolated DNA encoding Factor IX comprises a mutation encoding an alanine residue in place of lysine in the fifth amino acid position from the beginning of mature Factor IX.

2. The composition of claim 1, further comprising a portion of intron 1 of the Factor IX gene.

3. The composition of claim 2, wherein said portion of intron 1 of a Factor IX gene is from about 0.3 kb to about 1.7 kb.

4. The composition of claim 1 further comprising a pharmaceutically acceptable carrier.

5. The composition of claim 1, wherein said promoter/regulatory sequence comprises the cytomegalovirus immediate early promoter/enhancer.

6. The composition of claim 1, wherein said transcription termination signal is the SV40 transcription termination signal.

7. A kit comprising the pharmaceutical composition of claim 1.

8. The composition of claim 1 wherein said Factor IX is human Factor IX.

Details for Patent 7,998,734

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 1986-06-04 ⤷  Try it Free 2017-03-14
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try it Free 2017-03-14
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Express Scripts
Medtronic
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.